Biovail Partners with Alexza On Late-Stage CNS Drug For Schizophrenia Agitation
This article was originally published in The Pink Sheet Daily
Executive Summary
Biovail gets ready to rebuild a U.S. commercial team, while Alexza gets a cash infusion to fund its business through early 2011.
You may also be interested in...
Alexza's Inhaled Antipsychotic To Get Indication-Limiting REMS
Firm's proposed risk management plan may exclude patients with COPD or asthma. The application for AZ-004 is expected to be resubmitted by July, with an advisory committee likely by year end.
Alexza's Inhaled Antipsychotic To Get Indication-Limiting REMS
Firm's proposed risk management plan may exclude patients with COPD or asthma. The application for AZ-004 is expected to be resubmitted by July, with an advisory committee likely by year end.
Biovail Presses Forward With CNS Agenda
Canadian drug maker is planning to launch Staccato loxapine and embark on an ambitious clinical program for pimavanserin in 2011.